The EPS and revenue miss, combined with pipeline terminations and a 20% workforce reduction, signal near-term operational stress despite the two FDA approvals. The PRV sales provide a cash buffer, but the company's path to 2027 profitability depends on successful launches of GENGLYCOS and FAYUVI and continued cost discipline. Monitor Q4 2026 for restructuring charges and initial launch revenue from the two new gene therapies.
Drugs in focus
RARE drug pipeline →Evkeeza
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized since February 2021 (US) and June 2021 (EU). Latest label expansion (ages 1-5) approved September 2025.
- Next catalyst
- None dated
What to watchEvkeeza is a first-in-class ANGPTL3 inhibitor approved for an ultra-rare cholesterol disorder (HoFH, ~1,300 US patients). It is already de-risked by FDA approval but contributes only ~$130-150M in annual US sales versus Regeneron's ~$14.3B total revenue. The stock is primarily driven by Dupixent, EYLEA, and the broader pipeline, not this one drug. Watch quarterly Evkeeza US sales for gradual label-expansion uptake, but do not expect binary swings from this asset.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $17.16entry
- T+1 · 12d ago −9.27%α −4.86% · $15.57
- T+5 · 6d ago −2.68%α −1.77% · $16.70
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx reported Q3 2026 revenue of $173M (up 8% YoY from $160M) and a net loss of $118M ($1.16 per share), narrower than the $180M loss a year ago. The company announced a 20% headcount reduction, termination of two pipeline programs (GTX-102, UX701), and expects full-year GAAP profitability in 2027. Two FDA approvals (GENGLYCOS, FAYUVI) were received, and two Priority Review Vouchers were sold for a combined $413M. The EPS of -$1.16 missed the consensus estimate of -$0.75, a miss of 54.7%.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $173M vs $160M YoY (+8.1%)
- Net loss $118M ($1.16 per share) vs $180M ($1.81) YoY
- EPS of -$1.16 missed consensus of -$0.75 (54.7% miss)
- Revenue of $173M missed consensus of $183.7M (5.8% miss)
- Cash and securities $401M as of Sep 30, 2026, down from $737M at Dec 31, 2025
- Two PRVs sold for combined $413M; net proceeds ~$350M
- Headcount reduction of ~20% to ~1,000 employees
- R&D expense expected to be <$350M in 2027 (at least 50% reduction vs 2025)
- Termination of GTX-102 (Angelman) and UX701 (Wilson) programs
- Reaffirmed 2026 total revenue guidance $730M-$760M (excl. new launches)
- Expects full-year GAAP profitability in 2027
Financial Impact
Q3 revenue $173M vs consensus $183.7M (miss); EPS -$1.16 vs consensus -$0.75 (miss); cash burn $43M operating cash flow in Q3; PRV sales provide ~$350M net proceeds; restructuring charges ~$25M in Q4 2026
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| CRYSVITA | $109.0M | -2.7% |
| DOJOLVI | $30.0M | +25.0% |
| EVKEEZA | $24.0M | +41.2% |
| MEPSEVII | $10.0M | +42.9% |
Risk Factors
- EPS and revenue both missed consensus estimates by wide margins
- Cash burn continues; cash balance declined $336M from Dec 2025 to Sep 2026
- Pipeline terminations (GTX-102, UX701) reduce future growth optionality
- Restructuring execution risk and potential disruption to operations
- Dependence on successful launches of GENGLYCOS and FAYUVI for 2027 profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394751 |
Track record
22 reports on RARE
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Viewing Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers